Healthy Living/WellnessFDA Approves Alkermes' Aristada Drug As Schizophrenia Treatment Alkermes announced that the FDA has approved its extended-release injectable for schizophrenia treatment. Aristada, poised to be launched immediately, will offer once-a-month and six-week dosing options.by Katrina Pascual
Healthy Living/WellnessFDA Warns Heart Device Maker St. Jude About Nonconforming Manufacturing Practices At Atlanta Plantby Katrina Pascual
Healthy Living/WellnessLiquid Nicotine Can Kill: FDA Urged To Implement Rules For Warning Labels And Childproof Packagingby Rhodi Lee
Healthy Living/WellnessFDA Issues Approval For Bayer Autoinjector For Multiple Sclerosis Therapyby Dianne Depra
Healthy Living/WellnessMost Remedies For Hot Flashes Do Not Work But Here Are Treatments That Helpby Katherine Derla
Healthy Living/WellnessFDA Approves Oral Drug Lonsurf For Patients With Advanced Colon Cancerby Julienne Roman
Healthy Living/WellnessReports Of Health Complications Prompt FDA To Review Safety Of Essure Birth Control Implantby Julienne Roman
Healthy Living/WellnessFDA Greenlights Allergan Drug Vraylar For Schizophrenia And Bipolar Disorderby Julienne Roman
Healthy Living/WellnessFDA Gives Fast Track Approval To ZMapp Experimental Ebola Drugby Rina Marie Doctor
Healthy Living/WellnessPacira Locked In Legal Battle With Feds Over Exparel Marketingby Rina Marie Doctor
Healthy Living/WellnessFDA Sends Warning Letters To Producers Of Pure Powdered Caffeineby Rina Marie Doctor